LIVERPOOL, U.K. - eTradeWire -- Partners4Access (P4A), a global consultancy specializing in access strategy for orphan and rare diseases, proudly announces that Associate Consultant, Johann Sanseau will present his technical poster at the International Research Congress for Facioscapulohumeral Muscular Dystrophy (FSHD), taking place in Amsterdam this month.

Johann's poster, titled "Optimising Clinical Development Programs for FSHD Therapies in Preparation for Joint Clinical Assessment (JCA) in Europe," explores strategic approaches to aligning FSHD therapy development with the evolving regulatory and health technology assessment (HTA) landscape. As the European Union moves toward centralized JCA processes, Johann's research highlights critical considerations for developers navigating both clinical efficacy and payer expectations.

More on eTradeWire News

• Golden Intelligent Coin Trading Center Inc Expands Multi-Asset Trading Access
• The Starlight Bond: A Romantasy Saga - Ignites a New Dawn on Amazon
• Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
• Revenue Valve Tells Why Visual Storytelling Is the Secret Weapon for Healthcare Nonprofits
• Renowned Businessman, Acy Brown, Intertwines Philanthropy and Public Service in an Impactful Way

The acceptance of this work at one of the leading global forums for FSHD research reflects both Johann's commitment to advancing rare disease access and P4A's thought leadership in regulatory-HTA integration.

"FSHD is a relentlessly progressive rare disease with no treatment options to date. By the time both ATMP and orphan drug therapies for FSHD have completed clinical development, they will be subject to JCA." said Sophie Schmitz, Managing Partner at Partners4Access. "This work provides useful insights for drug developers on the PICOs that may be selected by member states."

The International Research Congress for FSHD will be held in Amsterdam from June 12-13, 2025.

About Partners4Access

Partners4Access is a global leader in pharmaceutical innovation and orphan drug access. With a global presence, we are dedicated to supporting our clients and access to life-changing therapies to patients worldwide.

Find out more at www.partners4access.com